As a commercial leader in the life sciences, what would you do if you were only allowed half the number of sales reps to bring your drug to market during (and after) the pandemic?
This and other questions are burning in the minds of many commercial leaders, as we all navigate the turbulence of COVID-19. With Phase 3 trials imminent or under way at multiple BioPharma companies, many commercial leaders are asking themselves: How will my sales reps sell to physicians? And what does that mean for the size and makeup of my commercial team?
As a commercial leader and senior HR executive in the BioPharma space, one of your biggest priorities in the commercialization process is building the right team, so watch our webinar to learn more about:
- Short and long-term impacts of COVID-19 on the commercialization process
- Capitalizing on new virtual engagement models
- Rethinking salesforce/market access utilization models (looking at both talent and budget)
Leading the webinar was Dave Melville, CEO & Founder of executive search firm, The Bowdoin Group, who shared his experiences from completing 50+ commercializations and real-world examples of how to hire talent for a successful commercial launch. Debbi Amanti Belanger, Managing Director at ClearView Healthcare Partners, a life sciences consulting firm, joined Dave to provide key insights. As part of the leadership team at ClearView, Debbi has been a thought partner for a range of pharma and biotech clients. While she has extensive experience across all major therapeutic areas and project types, she has particularly deep expertise in orphan diseases, oncology, workshop facilitation, and pricing & market access.
Do you have questions for our subject matter experts? Reach out to Justin Endres (Managing Director, Life Sciences) to answer questions related to your next BioPharma company build-out and commercial team expansion.